{
  "run_id": "75ae56d5-72e0-430f-a93d-0f93de6ea2a2",
  "prompt_variant_id": "3f26049e-5a6a-45a3-872c-e35805b5d524",
  "api_config_name": "model_gpt_3_5_turbo",
  "test_case_id": "breast_cancer_her2_positive",
  "start_time": "2025-09-01T14:38:59.507266",
  "end_time": "2025-09-01T14:39:02.026564",
  "duration_ms": 2510.530710220337,
  "success": true,
  "error_message": "",
  "entities_extracted": 16,
  "entities_mapped": 12,
  "extraction_completeness": 1.0,
  "mapping_accuracy": 0.3,
  "precision": 0.8235294117647058,
  "recall": 0.875,
  "f1_score": 0.8484848484848485,
  "compliance_score": 1.0,
  "token_usage": 3907,
  "extracted_entities": [
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 0.9,
      "source_context": {
        "section": "Conditions",
        "position": 11,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": null
      },
      "confidence": 0.9,
      "source_context": {
        "section": "Conditions",
        "position": 39,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 33,
        "context_sentence": "Histologically confirmed HER2-positive metastatic breast cancer",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Measurable disease per RECIST 1.1",
      "type": "condition",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 64,
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "ECOG performance status 0-1",
      "type": "demographic",
      "attributes": {},
      "confidence": 0.7,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 89,
        "context_sentence": "ECOG performance status 0-1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Adequate organ function",
      "type": "condition",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "INCLUSION CRITERIA",
        "position": 111,
        "context_sentence": "Adequate organ function",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Prior treatment with Trastuzumab Deruxtecan",
      "type": "exclusion",
      "attributes": {},
      "confidence": 0.9,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": 13,
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Active brain metastases",
      "type": "condition",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": 39,
        "context_sentence": "Active brain metastases",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Pregnancy or breastfeeding",
      "type": "condition",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "EXCLUSION CRITERIA",
        "position": 61,
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "novel HER2-targeted therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": "novel",
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": 19,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "temporal_context": "current"
      },
      "confidence": 0.8,
      "source_context": {
        "section": "briefSummary",
        "position": 53,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "progressed on prior trastuzumab-based therapy",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "temporal_context": "past"
      },
      "confidence": 0.7,
      "source_context": {
        "section": "briefSummary",
        "position": 99,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefTitle",
        "position": 23,
        "context_sentence": "Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Phase III Study",
      "type": "procedure",
      "attributes": {},
      "confidence": 0.8,
      "source_context": {
        "section": "officialTitle",
        "position": 2,
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Novel Targeted Therapy",
      "type": "medication",
      "attributes": {},
      "confidence": 0.85,
      "source_context": {
        "section": "officialTitle",
        "position": 12,
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "officialTitle",
        "position": 39,
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    }
  ],
  "Mcode_mappings": [
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Breast Cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 0",
      "mapping_rationale": "Mapped to CancerCondition as primary cancer diagnosis",
      "id": "07c711f9-a423-42f5-b3fb-9b99e22f4434",
      "llm_source_text_fragment": "Entity index 0",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic Breast Cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 1",
      "mapping_rationale": "Mapped to CancerCondition as cancer type",
      "id": "17ba5998-0536-4718-b461-c13c0dd3ec0f",
      "llm_source_text_fragment": "Entity index 1",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 2",
      "mapping_rationale": "Mapped to CancerCondition as specific cancer type",
      "id": "6359a008-016c-4922-8918-2dad878b4208",
      "llm_source_text_fragment": "Entity index 2",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Adequate organ function",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 5",
      "mapping_rationale": "Mapped to CancerCondition as condition related to organ function",
      "id": "47511f80-a2d6-4118-a0a2-262429cd8a9e",
      "llm_source_text_fragment": "Entity index 5",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Active brain metastases",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 7",
      "mapping_rationale": "Mapped to CancerCondition as condition related to brain metastases",
      "id": "0b56413e-bd8c-4a60-9a44-8db74e0d4a1c",
      "llm_source_text_fragment": "Entity index 7",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Pregnancy or breastfeeding",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 8",
      "mapping_rationale": "Mapped to CancerCondition as condition related to pregnancy or breastfeeding",
      "id": "dbdc29c3-5938-49f4-ac95-e4af330c9e87",
      "llm_source_text_fragment": "Entity index 8",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 10",
      "mapping_rationale": "Mapped to CancerCondition as specific cancer type",
      "id": "97949baa-719e-4109-bd36-7fd907333792",
      "llm_source_text_fragment": "Entity index 10",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "progressed on prior trastuzumab-based therapy",
      "mapping_confidence": 0.7,
      "source_text_fragment": "Entity index 11",
      "mapping_rationale": "Mapped to CancerCondition as disease status",
      "id": "118de335-413e-4899-914b-3f23760c6839",
      "llm_source_text_fragment": "Entity index 11",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Breast Cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 12",
      "mapping_rationale": "Mapped to CancerCondition as primary cancer diagnosis",
      "id": "40e66506-7708-4ae3-8c0b-fc77fceaf282",
      "llm_source_text_fragment": "Entity index 12",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Metastatic Breast Cancer",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 13",
      "mapping_rationale": "Mapped to CancerCondition as specific cancer type",
      "id": "f01cffd3-5c4b-4818-ab91-15976c500a0f",
      "llm_source_text_fragment": "Entity index 13",
      "source_references": []
    },
    {
      "resourceType": "Procedure",
      "Mcode_element": "CancerRelatedProcedure",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedprocedure",
        "display": "CancerRelatedProcedure"
      },
      "value": "Phase III Study",
      "mapping_confidence": 0.8,
      "source_text_fragment": "Entity index 16",
      "mapping_rationale": "Mapped to CancerRelatedProcedure as a study procedure",
      "id": "eeaab911-d15f-41c4-a87c-7efa0ac91493",
      "llm_source_text_fragment": "Entity index 16",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Novel Targeted Therapy",
      "mapping_confidence": 0.85,
      "source_text_fragment": "Entity index 17",
      "mapping_rationale": "Mapped to CancerRelatedMedication as a novel targeted therapy",
      "id": "fc54511d-8019-4880-a55c-4bef578c7b3b",
      "llm_source_text_fragment": "Entity index 17",
      "source_references": []
    }
  ],
  "validation_results": {
    "valid": true,
    "errors": [],
    "warnings": [],
    "compliance_score": 1.0
  }
}